Probenecid as a noninjurious positive inotrope in an ischemic heart disease murine model

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 3, 2013, Pages 280-289

  Koch, Sheryl E ^a   Tranter, Michael ^a   Robbins, Nathan ^a   Luther, Kristin ^b   Singh, Umesh ^a   Jiang, Min ^a   Ren, Xiaoping ^b   Tee, Trisha ^a   Smith, Leah ^a   Varma, Priyanka ^a   Jones, W Keith ^b   Rubinstein, Jack ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Ca2+ influx; Echocardiography; Infarct; Inotrope; Ischemia reperfusion

Indexed keywords

CALCIUM; ISOPRENALINE; PROBENECID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CELL DEATH; CONTROLLED STUDY; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; ISCHEMIC HEART DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ADMINISTRATION, ORAL; ANIMALS; CALCIUM SIGNALING; CARDIOTONIC AGENTS; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HEART; INJECTIONS, INTRAPERITONEAL; KINETICS; MALE; MEMBRANE TRANSPORT MODULATORS; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROBENECID; RANDOM ALLOCATION;

EID: 84879230808     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248412469299     Document Type: Article

References (34)

1. Gheorghiade M, Zannad F, Spoko G, et al. Acute heart failure syndromes. Current state and framework for future research. Circulation. 2005;112(25):3958-3968.
2. Goldhaber JI, Hamilron MA. Role of inotropic agents in the treatment of heart failure. Circulation. 2010;121(14):1655-1660.
3. Abraham WT, Adams KF, Fonarow GS, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46(1):57-64.
4. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence based approach. Am Heart J. 2001;142(3):393-401.
5. Burger AJ, Elkayam U, Naibaur MT, et al. Comparison of the occurrence of ventriculary arrhtyhmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol. 2001;88(1):35-39.
6. Singh K, Xiao L, Remondino A, Sawyer DB, Colucci WS. Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol. 2001;189(3):257-265.
7. Hasenfuss G, Holubarsch C, Blanchard EM, Mulieri LA, Alpert NR, Just HJ. Influence of isoproterenol on myocardial energetics. Experimental and clinical investigations. Basic Res Cardiol. 1989;84(suppl 1):147-155.
8. Koch SE, Gao X, Haar L, et al. Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation. J Mol Cell Cardiol. 2012;53(1):134-144.
9. Choudhury MR, Hassan MM, Hakim F, Haq SA. Review on treatment of gout & hyperuricemia. J Bangladesh Coll Phys Surg. 2011;29:85-95.
10. Robbins N, Koch SE, Tranter M, Rubinstein J. The history and future of probenecid. Cardiovasc Toxicol. 2012;12(1):1-9.
11. Butler D. Wartime tactics doubles power of scarce bird-flu drug. Nature. 2005;438(7064):6.
12. Boger WP, Pitts FW, Gallagher ME. Benemid and carinamide: comparison of effect on para-amino-salicylic acid (PAS) plasma concentrations. J Lab Clin Med. 1950;36(2):276-282.
13. Bang S, Kim KY, Too S, Lee SH, Hwang SW. Transient receptor potential V2 expressed in sensory neurons is activated by probenecid. Neurosci Lett. 2007;425(2):120-125.
14. Ren X, Wang Y, Jones WK. TNF-a is required for late ischemic preconditioning but not for remote preconditioning of trauma. J Surg Res. 2004;121(1):120-129.
15. Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R. Demonstration of an early and a late phase of ischemic preconditioning in mice. Am J Physiol. 1998;275(4pt 2):H1375-H1387.
16. Jones WK, Fan GC, Liao S, et al. Peripheral nociception associated with surgical incision elicits remote nonischemic cardioprotection via neurogenic activation of protein kinase C signaling. Circulation. 2009;120(11 suppl):S1-S9.
17. Shizukuda Y, Buttrick PM, Geenen DL, Borczuk AC, Kitsis RN, Sonneblick EH. b-Adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol. 1998;275(3 pt 2):H961-H968.
18. Saito S, Hiroi Y, Zou Y,et al. b-adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem. 2000;275(44):34528-34533.
19. Clark MG, Patten GS. Adrenergic regulation of glucose metabolism in rat heart. A calcium dependent mechanism mediated by both alpha and beta adrenergic receptors. J Biol Chem. 1984; 25(24):15204-15211.
20. Hu A, Jiao X, Gao E, et al. Chronic b-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemia/ reperfusion injury by provoking inducible nitric-oxide synthase-mediated nitrative stress. J Pharm Exp Ther. 2006; 318(2):469-475.
21. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuos intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the FLolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(1):78-86.
22. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39(5):798-803.
23. Bayram M, De Luca L, MassieMB, Gheorghiade M. Reassessment of cobutamine, dopamine and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005;96(6):47-58.
24. Houser SR, Margulies KB, Murphy AM, et al. Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res. 2012;111(1):131-150.
25. Foster FS, Mehi J, Lukacs M, et al. A new 15-50 MHz array-based micro-ultrasound scanner for preclinical imaging. Ultrasound Med Biol. 2009;35(10):1700-1708.
26. Everaerts W, Vriens J, Owsianik G, et al. Functional characterization of transient receptor potential channels in mouse urothelial cells. Am J Physiol Renal Physiol. 2010;298(3):F692-F701.
27. Hisanaga E, Nagasawa M, Ueki K, Kulkarni RN, Mori M, Kojima I. Regulation of calcium-permeable TRPV2 channel by insulin in pancreatic b-Cells. Diabetes. 2009;58(1):174-184.
28. Boels K, Glassmeier G, Herrmann D, et al. The neuropeptide head activator induces activation and translocation of the growth-factor-regulated Ca(2+)-permeable channel GRC. J Cell Sci. 2001;114(pt 20):3599-3606.
29. Kanzaki M, Zhang YQ, Mashima H, Li L, Shibata H, Kojima I. Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I. Nat Cell Biol. 1999;1(3):165-170.
30. Rutter AR, Ma QP, Leveridge M, Bonnert TP. Heteromerization and colocalization of TrpV1 and TrpV2 in mammalian cell lines and rat dorsal root ganglia. Neuroreport. 2005; 16(16):1735-1739.
31. Penna A, Juvin V, Chemin J, Compan V, Monet M, Rassendren F-A. PI3-kinase promotes TRPV2 activity independently of channel translocation to the plasma membrane. Cell Calcium. 2006;39(6):495-507.
32. Nagasawa M, Nakagawa Y, Tanaka S, Kojima I. Chemotactic Peptide fMetLeuPhe Induces Translocation of the TRPV2 Channel in Macrophages. J Cell Physiol. 2007;210(3):692-702.
33. Frederick J, Buck ME, Matson DJ, Contright DN. Increased TRPA1, TRPM8 and TRPV2 expression in dorsal root ganglia by nerve injury. Biochem Biophys Res Commun. 2007;358(4): 1058-1064.
34. Maroko PR, Kjekshus JK, Sobel BE, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971;43(1):67-82.